– IRELAND, Bray – Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, announced the appointment of Paul Tivnan to its Board as a Non-Executive Director, bringing over 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors.
About Paul Tivnan
Paul Tivnan serves as CFO of Deriva Energy LLC, one of the largest independent renewable power producers in the USA and a Brookfield portfolio company. His previous roles include CFO of Brookfield Renewable Ireland and CFO of Ardmore Shipping Corporation, where he led the company’s successful IPO on the New York Stock Exchange in 2013. Paul Tivnan has also served as a Director of Element 1 Corp, a developer of advanced hydrogen technologies.
Paul Tivnan is a Certified International Director from INSEAD Business School and has completed executive leadership and corporate governance programs at INSEAD and London Business School. Earlier in his career, he worked at Ernst & Young in Financial Services Advisory, specializing in international tax and corporate structuring.
Paul Tivnan holds a B.A. degree in Accounting and Finance and a Master of Business Studies degree from Dublin City University. He is a Fellow of the Institute of Chartered Accountants of Ireland, a Chartered Tax Advisor, and a member of the Institute of Chartered Shipbrokers.
About Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma, and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide.
For more information: https://www.trinitybiotech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.